BIIBBIOGEN INC.
Biological Products, (no Diagnostic Substances)
- Revenue
- $9.9B
- 2.2% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$2.9B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear171% of net incomeCash flow under 80% of net income
- Dilutive SBCClear3% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear22% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $11.0B | $10.2B | $9.8B | $9.7B | $9.9B | 2.2% |
| Operating income | $2.8B | — | — | — | — | |
| Net income | $1.6B | $3.0B | $1.2B | $1.6B | $1.3B | 21% |
| Operating cash flow | $3.6B | $1.4B | $1.5B | $2.9B | $2.2B | 23% |
| Capex | $258M | $240M | $277M | $154M | $154M | 0.1% |
| Stock-based comp | $239M | $254M | $264M | $291M | $291M | 0.1% |
| Buybacks | $1.8B | $750M | $0 | $0 | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 72 | 120 |
| FY2024 | — | — | 62 | 91 |
| FY2023 | — | — | 106 | 92 |
| FY2022 | — | — | 113 | 89 |
| FY2021 | — | — | 98 | 99 |